Insiders · RVNC

RVNC insider transactions

Revance Therapeutics Inc. (RVNC) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.

RVNC insiders

Everyone who has filed a Form 3, 4, 5 or 144 at Revance Therapeutics Inc., latest first. Follow anyone to get their next filing.

• Julian S GangolliDirector
• Mark J FoleyPresident & CEO, Director+$725K-$6.87M
• Tobin SchilkeCFO-$2.07M
• Dwight MoxieClo & GC-$2.33M
• David HollanderCMO & Global Therapeutics Lead, since February 2024-$16.3K
• Erica JordanChief Commercial Officer, since February 2024-$9,096
• Olivia C WareDirector, since March 2021
• Carey OConnor KolajaDirector, since March 2021-$70.6K
• Vlad CoricDirector
• Jill BeraudDirector
• Chris NoletDirector
• Angus C. RussellDirector+$101K
• Dustin S SjutsPresident-$1.61M
• Philip J. VickersDirector
• Abhay JoshiOfficer
• Aubrey RankinDirector+$433K-$4.98M

Recent Form 3, 4, and 5 filings for RVNC

• 644d
  Director Gangolli Julian S returned 15,000 shares to the company, closing all direct ownership in the company (SEC Form 4)

  4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
• 644d
  President & CEO Foley Mark J returned 112,619 shares to the company and was granted 84,686 shares, closing all direct ownership in the company (SEC Form 4)

  4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
• 644d
  CFO Schilke Tobin returned 124,438 shares to the company and was granted 20,883 shares, closing all direct ownership in the company (SEC Form 4)

  4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
• 644d
  CLO & GC Moxie Dwight returned 114,104 shares to the company and was granted 18,125 shares, closing all direct ownership in the company (SEC Form 4)

  4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
• 644d
  CMO & Global Therapeutics Lead Hollander David returned 95,212 shares to the company, closing all direct ownership in the company (SEC Form 4)

  4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
• 644d
  Chief Commercial Officer Jordan Erica returned 107,942 shares to the company, closing all direct ownership in the company (SEC Form 4)

  4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
• 644d
  Director Ware Olivia C returned 15,000 shares to the company, closing all direct ownership in the company (SEC Form 4)

  4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
• 644d
  Director Kolaja Carey Oconnor returned 15,000 shares to the company, closing all direct ownership in the company (SEC Form 4)

  4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
• 644d
  Director Coric Vlad returned 15,000 shares to the company, closing all direct ownership in the company (SEC Form 4)

  4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
• 644d
  Director Beraud Jill returned 15,000 shares to the company, closing all direct ownership in the company (SEC Form 4)

  4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
• 644d
  Director Nolet Chris returned 15,000 shares to the company, closing all direct ownership in the company (SEC Form 4)

  4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
• 644d
  Director Russell Angus C. returned 15,000 shares to the company, closing all direct ownership in the company (SEC Form 4)

  4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
• 645d
  CEO Foley Mark J was granted 27,933 shares, increasing direct ownership by 3% to 1,024,868 units (SEC Form 4)

  4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
• 645d
  CLO & GC Moxie Dwight was granted 5,979 shares, increasing direct ownership by 4% to 143,794 units (SEC Form 4)

  4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
• 645d
  CFO Schilke Tobin was granted 6,888 shares, increasing direct ownership by 4% to 201,554 units (SEC Form 4)

  4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
• 678d
  CEO Foley Mark J was granted 1,000 shares, increasing direct ownership by 0.10% to 996,935 units (SEC Form 4)

  4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
• 678d
  CFO Schilke Tobin was granted 1,000 shares, increasing direct ownership by 0.52% to 194,666 units (SEC Form 4)

  4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
• 723d
  CMO & Global Therapeutics Lead Hollander David sold $16,296 worth of shares (3,908 units at $4.17), decreasing direct ownership by 4% to 104,945 units (SEC Form 4)

  4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
• 863d
  CEO Foley Mark J was granted 1,000 shares, increasing direct ownership by 0.10% to 995,935 units (SEC Form 4)

  4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
• 863d
  CFO Schilke Tobin was granted 1,000 shares, increasing direct ownership by 0.52% to 193,666 units (SEC Form 4)

  4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
• 924d
  Ware Olivia C was granted 15,000 shares, increasing direct ownership by 90% to 31,675 units (SEC Form 4)

  4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
• 924d
  Russell Angus C. was granted 15,000 shares, increasing direct ownership by 41% to 51,506 units (SEC Form 4)

  4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
• 924d
  Nolet Chris was granted 15,000 shares, increasing direct ownership by 52% to 43,606 units (SEC Form 4)

  4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
• 924d
  Kolaja Carey Oconnor was granted 15,000 shares, increasing direct ownership by 91% to 31,561 units (SEC Form 4)

  4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
• 924d
  Gangolli Julian S was granted 15,000 shares, increasing direct ownership by 50% to 45,106 units (SEC Form 4)

  4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
• 924d
  Coric Vlad was granted 15,000 shares, increasing direct ownership by 259% to 20,784 units (SEC Form 4)

  4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
• 924d
  Beraud Jill was granted 15,000 shares, increasing direct ownership by 52% to 43,606 units (SEC Form 4)

  4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
• 939d
  Jordan Erica sold $9,096 worth of shares (2,392 units at $3.80), decreasing direct ownership by 2% to 114,864 units (SEC Form 4)

  4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
• 968d
  Sjuts Dustin S covered exercise/tax liability with 2,967 shares and sold $46,446 worth of shares (9,211 units at $5.04), decreasing direct ownership by 7% to 167,550 units (SEC Form 4)

  4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
• 968d
  Moxie Dwight covered exercise/tax liability with 3,269 shares and sold $40,971 worth of shares (8,125 units at $5.04), decreasing direct ownership by 8% to 137,815 units (SEC Form 4)

  4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
• 968d
  Schilke Tobin covered exercise/tax liability with 3,822 shares and sold $47,204 worth of shares (9,361 units at $5.04), decreasing direct ownership by 6% to 192,666 units (SEC Form 4)

  4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
• 968d
  Foley Mark J covered exercise/tax liability with 20,533 shares, decreasing direct ownership by 2% to 994,935 units (SEC Form 4)

  4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
• 979d
  Foley Mark J bought $209,400 worth of shares (30,000 units at $6.98), increasing direct ownership by 3% to 1,015,468 units (SEC Form 4)

  4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
• 983d
  Sjuts Dustin S was granted 22,110 shares, increasing direct ownership by 14% to 179,728 units (SEC Form 4)

  4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
• 983d
  Moxie Dwight was granted 15,143 shares, increasing direct ownership by 11% to 149,209 units (SEC Form 4)

  4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
• 983d
  Schilke Tobin was granted 17,447 shares, increasing direct ownership by 9% to 205,849 units (SEC Form 4)

  4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
• 983d
  Foley Mark J was granted 70,750 shares, increasing direct ownership by 8% to 985,468 units (SEC Form 4)

  4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
• 987d
  New insider Jordan Erica claimed ownership of 117,256 shares (SEC Form 3)

  3 - Revance Therapeutics, Inc. (0001479290) (Issuer)
• 987d
  New insider Hollander David claimed ownership of 108,853 shares (SEC Form 3)

  3 - Revance Therapeutics, Inc. (0001479290) (Issuer)
• 1014d
  Moxie Dwight was granted 90,000 shares, increasing direct ownership by 204% to 134,066 units (SEC Form 4)

  4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
• 1014d
  Schilke Tobin was granted 96,667 shares, increasing direct ownership by 105% to 188,402 units (SEC Form 4)

  4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
• 1014d
  SEC Form 4 filed by Foley Mark J

  4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
• 1044d
  Sjuts Dustin S was granted 264 shares, increasing direct ownership by 0.17% to 157,618 units (SEC Form 4)

  4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
• 1044d
  Schilke Tobin was granted 434 shares, increasing direct ownership by 0.48% to 91,735 units (SEC Form 4)

  4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
• 1044d
  Foley Mark J was granted 264 shares, increasing direct ownership by 0.03% to 914,718 units (SEC Form 4)

  4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
• 1060d
  Sjuts Dustin S covered exercise/tax liability with 4,712 shares, decreasing direct ownership by 3% to 157,354 units (SEC Form 4)

  4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
• 1162d
  SEC Form 4: Moxie Dwight sold $612,624 worth of shares (34,853 units at $17.58), decreasing direct ownership by 44% to 44,066 units

  4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
• 1185d
  SEC Form 4: Schilke Tobin was granted 22,620 shares and covered exercise/tax liability with 11,215 shares, increasing direct ownership by 14% to 91,301 units

  4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
• 1185d
  SEC Form 4: Moxie Dwight was granted 19,346 shares and covered exercise/tax liability with 9,592 shares, increasing direct ownership by 14% to 78,919 units

  4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
• 1185d
  SEC Form 4: Sjuts Dustin S covered exercise/tax liability with 8,901 shares and was granted 22,620 shares, increasing direct ownership by 9% to 162,066 units

  4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
• 1185d
  SEC Form 4: Foley Mark J was granted 122,143 shares and covered exercise/tax liability with 48,064 shares, increasing direct ownership by 9% to 914,454 units

  4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
• 1196d
  SEC Form 4: Foley Mark J sold $593,151 worth of shares (26,279 units at $22.57), decreasing direct ownership by 3% to 840,375 units

  4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
• 1226d
  SEC Form 4 filed by Schilke Tobin

  4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
• 1226d
  SEC Form 4 filed by Sjuts Dustin S

  4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
• 1226d
  SEC Form 4 filed by Foley Mark J

  4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
• 1241d
  SEC Form 4 filed by Kolaja Carey Oconnor

  4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
• 1248d
  SEC Form 4 filed by Sjuts Dustin S

  4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
• 1248d
  SEC Form 4 filed by Foley Mark J

  4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
• 1256d
  SEC Form 4 filed by Schilke Tobin

  4 - Revance Therapeutics, Inc. (0001479290) (Issuer)
• 1276d
  SEC Form 4 filed by Moxie Dwight

  4 - Revance Therapeutics, Inc. (0001479290) (Issuer)